Similarly, IHC results show that compared with single drug treatment, combined treatment with PTC-209 and Bevacizumab can effectively promote the expression of E-cadherin and inhibit the expression of Ki-67, indicating that combined treatment can effectively reduce the EMT and proliferation levels of NSCLC (Fig. 6F). The gene discussed is MKI67; the disease is non-small cell lung carcinoma.